Heuft Hans-Gert, Fischer Eike, Weingand Tina, Burkhardt Thomas, Leitner Gerda, Baume Hagen, Schmidt Jörg-Peter, Buser Andreas, Fauchald Gabriele, Reinicke Voigt Ute, Mansouri-Taleghani Behrouz
Institute for Transfusion Medicine, Hanover Medical School, Hanover, Germany.
Aix-Scientifics®, Clinical Research Organisation, Aachen, Germany.
Transfus Med Hemother. 2017 Jun;44(3):188-200. doi: 10.1159/000452107. Epub 2016 Nov 28.
Currently, there is an extensive but highly inconsistent body of literature regarding donor adverse events (AEs) in haemapheresis. As the reports diverge with respect to types and grading of AEs, apheresis procedures and machines, the range of haemapheresis-related AEs varies widely from about 0.03% to 6.6%.
The German Society for Transfusion Medicine and Immunohaematology (DGTI) formed a 'Haemapheresis Vigilance Working Party' (Arbeitsgemeinschaft Hämapheresevigilanz; AGHV) to create an on-line registry for comprehensive and comparable AE assessment with all available apheresis devices in all types of preparative haemapheresis: plasmapheresis (PLS), plateletpheresis (PLT), red blood cell apheresis, all kind of leukaphereses (autologous/allogeneic blood stem cell apheresis, granulocyte apheresis, lymphocyte/monocyte apheresis) and all possible types of multi-component apheresis. To ensure the comparability of the data, the AGHV adopted the 'Standard for Surveillance of Complications Related to Blood Donation' from the International Society for Blood Transfusion in cooperation with the International Haemovigilance Network (IHN) and the American Association of Blood Banks for AE acquisition and automated evaluation. The registry is embedded in a prospective observational multi-centre study with a study period of 7 years.
A preliminary evaluation encompassed the time period from January, 2012 to December, 2015. During this time, the system proved to be safe and stable. Out of approximately 345,000 haemaphereses 16,477 AEs were reported (4.9%) from 20 participating centres. The majority of AEs occurred in PLSs (63%), followed by PLT (34.5%) and SC (2.2%). Blood access injuries (BAI) accounted for about 55% of the supplied AEs, whereas citrate toxicity symptoms, vasovagal reactions and technical events (e.g. disposable leakages, software failures) rather equally affected haemaphereses at 8-15%. Out of 12,348 finalized AEs, 8,759 (70.1%) were associated with a procedure-related break-off, with BAI being the prevailing cause (5,463/8,759; 62.4%). An automated centre- and procedure-specific AE evaluation according to the latest IHN standard and AGHV pre-settings is available within a few minutes.
An on-line electronic platform for comprehensive assessment and centre-specific automated evaluation of AEs in haemaphereses has been developed and proved to be stable and safe over a period of 4 years.
目前,关于血液单采中供者不良事件(AE)的文献数量众多,但高度不一致。由于这些报告在不良事件的类型和分级、单采程序及机器方面存在差异,与血液单采相关的不良事件发生率范围差异很大,约为0.03%至6.6%。
德国输血医学与免疫血液学协会(DGTI)成立了一个“血液单采监测工作组”(Arbeitsgemeinschaft Hämapheresevigilanz;AGHV),以创建一个在线登记系统,用于对所有类型的制备性血液单采中所有可用的单采设备进行全面且可比的不良事件评估:血浆置换(PLS)、血小板单采(PLT)、红细胞单采、各类白细胞单采(自体/异体造血干细胞单采、粒细胞单采、淋巴细胞/单核细胞单采)以及所有可能类型的多成分单采。为确保数据的可比性,AGHV与国际输血协会、国际血液监测网络(IHN)以及美国血库协会合作,采用了“献血相关并发症监测标准”来获取不良事件并进行自动评估。该登记系统嵌入了一项为期7年的前瞻性观察性多中心研究。
初步评估涵盖了2012年1月至2015年12月期间。在此期间,该系统被证明是安全稳定的。在约345,000次血液单采中,20个参与中心报告了16,477例不良事件(4.9%)。大多数不良事件发生在血浆置换中(63%),其次是血小板单采(34.5%)和干细胞采集(2.2%)。血管通路损伤(BAI)约占所报告不良事件的55%,而枸橼酸盐毒性症状、血管迷走神经反应和技术事件(如一次性用品泄漏、软件故障)对血液单采的影响相当,均为8% - 15%。在12,348例最终确定的不良事件中,8,759例(70.1%)与操作相关的中断有关,血管通路损伤是主要原因(5,463/8,759;62.4%)。根据最新的IHN标准和AGHV预设进行的特定中心和操作的不良事件自动评估可在几分钟内完成。
已开发出一个用于全面评估血液单采中不良事件并进行特定中心自动评估的在线电子平台,且在4年期间被证明是稳定和安全的。